Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
CC transcript
Asset disposition
Inv. presentation
Director departure
HOLOGIC INC (HOLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/31/2023 8-K Quarterly results
05/01/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "HOLOGIC, INC. AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN",
"HOLOGIC, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN"
02/01/2023 8-K Quarterly results
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023 – Revenue of $1,074.2 Million Exceeds Guidance – – 15.8% Organic Constant Currency Growth in Diagnostics ex-COVID – – 24.5% Organic Constant Currency Growth in Molecular Diagnostics ex-COVID – – 14.7% Organic Constant Currency Growth in Surgical –"
12/09/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
09/23/2022 8-K Other Events  Interactive Data
08/30/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/27/2022 8-K Quarterly results
Docs: "Hologic Announces Financial Results for Third Quarter of Fiscal 2022 – Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations – – Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency – – Company Again Increases Full-Year Revenue and EPS Guidance –"
04/27/2022 8-K Quarterly results
Docs: "Hologic Announces Financial Results for Second Quarter of Fiscal 2022 – Revenue of $1.436 Billion, GAAP Diluted EPS of $1.80, and Non-GAAP Diluted EPS of $2.07 All Significantly Ahead of Expectations – – Company Again Increases Full-Year Revenue and EPS Guidance –"
03/11/2022 8-K Quarterly results
02/02/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022 – Revenue of $1,471.1 Million Significantly Exceeds Guidance – – Organic Revenue Grows 9% Excluding COVID-19 Benefits – – More than 8% Global Organic Growth in All Businesses: Breast, Surgical, Skeletal and Diagnostics ex-COVID –"
11/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Performance Stock Unit Award Agreement (ROIC) (adopted fiscal 2022)",
"Form of Performance Stock Unit Award Agreement (relative TSR) (adopted fiscal 2022)",
"Form of Performance Stock Unit Award Agreement (FCF) (adopted fiscal 2022)",
"Form of Performance Stock Unit Award Agreement (ROIC – Outside US) (adopted fiscal 2022)",
"Form of Performance Stock Unit Award Agreement (relative TSR – Outside US) (adopted fiscal 2022)",
"Form of Performance Stock Unit Award Agreement (FCF – Outside US) (adopted fiscal 2022)"
11/01/2021 8-K Quarterly results
Docs: "Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021 – Revenue of $1.317 Billion Exceeds Expectations – – Company Posts GAAP Diluted EPS of $1.28, Non-GAAP Diluted EPS of $1.61 – – Financial Guidance for Fiscal 2022 Anticipates Solid Growth in Core Women’s Health Businesses and Continued Contributions to COVID-19 Fight –"
09/27/2021 8-K Quarterly results
07/28/2021 8-K Quarterly results
Docs: "Hologic Announces Financial Results for Third Quarter of Fiscal 2021 — Revenue of $1.168 Billion Increases 42.0%, 37.8% in Constant Currency — — Organic Revenue Increases 38.4%, 34.2% in Constant Currency — — Company Posts GAAP Diluted EPS of $1.04, Non-GAAP Diluted EPS of $1.33"
06/17/2021 8-K Quarterly results
04/28/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
01/27/2021 8-K Quarterly results
Docs: "Hologic Announces Financial Results for First Quarter of Fiscal 2021 – Revenue of $1.61 Billion Increases 89.3%, 86.5% in Constant Currency – – Organic Revenue Increases 107.0%, 104.0% in Constant Currency – – Company Posts GAAP Diluted EPS of $2.50, Non-GAAP Diluted EPS of $2.86 –"
01/08/2021 8-K Quarterly results
11/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Performance Stock Unit Award Agreement (ROIC) (adopted fiscal 2021)",
"Form of Performance Stock Unit Award Agreement (relative TSR) (adopted fiscal 2021)",
"Form of Performance Stock Unit Award Agreement (FCF) (adopted fiscal 2021)",
"Form of Performance Stock Unit Award Agreement (ROIC – Outside US) (adopted fiscal 2021)",
"Form of Performance Stock Unit Award Agreement (relative TSR – Outside US) (adopted fiscal 2021)",
"Form of Performance Stock Unit Award Agreement (FCF – Outside US) (adopted fiscal 2021)"
11/04/2020 8-K Quarterly results
Docs: "Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020 — Revenue of $1.347 Billion Increases 55.6%, 54.2% in Constant Currency — — Organic Revenue Increases 72.5%, 70.9% in Constant Currency, as Strong Sales of COVID Tests Offset Declines in Other Businesses — — Company Posts GAAP Diluted EPS of $1.88, Non-GAAP Diluted EPS of $2.07"
10/15/2020 8-K Quarterly results
10/06/2020 8-K Quarterly results
09/28/2020 8-K Quarterly results
09/15/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: ". The Executive agrees that, with the exception of the Accrued Obligations due to him in accordance with the terms hereunder, that the payment of any severance under this Agreement to the Executive by the Company, is subject to and conditioned on Executive executing a general release of the Company in a form and scope determined by the Company in its sole discretion , without Executive revoking such Release Agreement within fifty-two days of the Date of Termination and provided that if the Date of Termination occurs in one calendar year and the Consideration Period expires during the following calendar year, then notwithstanding anything herein to the contrary, the payments of severance under Section 6 will be paid by the Company to the Executive in the second calendar year; the Executive ..."
09/14/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hologic Announces Offering of $950 Million of Senior Notes Due 2029"
09/11/2020 8-K Regulation FD Disclosure  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy